BioBridge is a hybrid advisory + platform business capturing an underserved corridor: high-potential biotech and scientific technology from Latin America, reaching companies, investors, and partners in Europe. We are raising to scale dealflow, technology, and team.
Technology transfer is a global, multi-billion dollar industry — and LATAM's participation is structurally limited by exactly the gaps BioBridge is built to close.
BioBridge does not wait for platform scale to generate revenue. Advisory services and curated dealflow monetize from the first technologies onboarded.
This is not a database business. The moat is relational, reputational, and compounding.
In our MVP validation phase, we are already generating real dealflow, advisory revenue, and cross-border matches — the metrics that matter most pre-scale.
A disciplined, three-phase path — validating commercial fundamentals before scaling technology and capital intensity.
Funding is allocated to deepen dealflow capacity, strengthen the technology layer, and expand the team driving Phase 2.
BioBridge is built by a team that combines scientific credibility with business execution — the rare combination this market requires.
Request the full investor deck — including detailed financial model, cap table structure, and complete pipeline data — and let's schedule a call.